Mostrar el registro sencillo del ítem
Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)
| dc.contributor.author | Caponcello, Maria Giulia | |
| dc.contributor.author | Macías Sánchez, Maria del Mar | |
| dc.contributor.author | Macías, Juan | |
| dc.contributor.author | Aguilar Guisado, Manuela | |
| dc.contributor.author | Romero Palacios, Alberto | |
| dc.contributor.author | Retamar Gentil, Pilar | |
| dc.contributor.author | Márquez-Gómez, Ignacio | |
| dc.contributor.author | Martínez-Marcos, Francisco Javier | |
| dc.contributor.author | López Cardenas, Salvador | |
| dc.contributor.author | Marrugal Lorenzo, Jose Antonio | |
| dc.contributor.author | Quijano Ruiz, Blanca | |
| dc.contributor.author | Mata, Rosario | |
| dc.contributor.author | Carmona Sánchez, Gloria | |
| dc.contributor.author | Oyonarte, Salvador | |
| dc.contributor.author | Rodríguez Baño, Jesús | |
| dc.contributor.other | Cirugía | es_ES |
| dc.contributor.other | Medicina | es_ES |
| dc.date.accessioned | 2026-11-11T11:08:37Z | |
| dc.date.available | 2026-11-11T11:08:37Z | |
| dc.date.issued | 2026-03-31 | |
| dc.identifier.issn | 1578-1852 | |
| dc.identifier.issn | 0213-005X | |
| dc.identifier.uri | http://hdl.handle.net/10498/40626 | |
| dc.description.abstract | Introduction: A phase 2 trial was conducted to evaluate the safety and efficacy of convalescent plasma (CP) for patients admitted with COVID-19 in the pre-vaccine era. Methods: CP was compared to standard of care (SoC) in a randomized clinical trial in patients admitted with COVID-19 pneumonia and with either hypoxia and/or some underlying condition from April to December 2020 in 15 hospitals in Andalusia, Spain. The primary endpoints were adverse events and failure (all-cause death and need for mechanical ventilation during the first 21 days). Result: The procedure for CP was developed and worked properly. Overall, 72 patients of 88 evaluated were recruited (37 and 35) assigned to CP and SoC. Median duration of COVID-19 related symptoms was 7 and 6 days, and median oxygen saturation at randomization was 93% and 92.5% in experimental and control arms, respectively. Overall, 8 (21.6%) patients in the experimental CP group (non related to CP) and 8 (22.9%) in the control group developed grade 3 adverse events (relative risk [RR] 0.94; 95% CI: 0.39–2.24); failure occurred in 3 (8.1%) and 4 (11.4%) patients, respectively ([RR] 0.94, CI: 0.14–6.35 for both events). No differences in secondary endpoints (change in inflammatory parameters, negativization of SARS-CoV-2 PCR or duration of hospital stay) were found. Conclusions: The results suggested that CP is safe for use in COVID-19 patients, although no significant efficacy signal could be observed. A successful regional system for CP administration was developed. | es_ES |
| dc.format | application/pdf | es_ES |
| dc.language.iso | eng | es_ES |
| dc.publisher | ELSEVIER | es_ES |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | es_ES |
| dc.source | Enfermedades Infecciosas y Microbiologia Clinica, Vol. 44, Núm. 6, 2026 | es_ES |
| dc.subject | COVID-19 | es_ES |
| dc.subject | Convalescent plasma | es_ES |
| dc.subject | Clinical trial | es_ES |
| dc.title | Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID) | es_ES |
| dc.type | journal article | es_ES |
| dc.rights.accessRights | open access | es_ES |
| dc.identifier.doi | 10.1016/J.EIMC.2026.503166 | |
| dc.type.hasVersion | VoR | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos Científicos [12034]
